oraverse Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Oraverse, and when can generic versions of Oraverse launch?
Oraverse is a drug marketed by Septodont Holding and is included in one NDA.
The generic ingredient in ORAVERSE is phentolamine mesylate. There are four drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the phentolamine mesylate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Oraverse
A generic version of oraverse was approved as phentolamine mesylate by HIKMA on March 11th, 1998.
Summary for oraverse
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 110 |
Clinical Trials: | 6 |
Patent Applications: | 1,014 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for oraverse |
What excipients (inactive ingredients) are in oraverse? | oraverse excipients list |
DailyMed Link: | oraverse at DailyMed |
Recent Clinical Trials for oraverse
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Cairo University | Phase 3 |
sara nabil | Phase 3 |
Dalhousie University | Phase 4 |
Pharmacology for oraverse
Drug Class | alpha-Adrenergic Blocker |
Mechanism of Action | Adrenergic alpha-Antagonists |
Anatomical Therapeutic Chemical (ATC) Classes for oraverse
US Patents and Regulatory Information for oraverse
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Septodont Holding | ORAVERSE | phentolamine mesylate | INJECTABLE;INJECTION | 022159-001 | May 9, 2008 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for oraverse
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Septodont Holding | ORAVERSE | phentolamine mesylate | INJECTABLE;INJECTION | 022159-001 | May 9, 2008 | ⤷ Try a Trial | ⤷ Try a Trial |
Septodont Holding | ORAVERSE | phentolamine mesylate | INJECTABLE;INJECTION | 022159-001 | May 9, 2008 | ⤷ Try a Trial | ⤷ Try a Trial |
Septodont Holding | ORAVERSE | phentolamine mesylate | INJECTABLE;INJECTION | 022159-001 | May 9, 2008 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for oraverse
See the table below for patents covering oraverse around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Cyprus | 1107617 | ⤷ Try a Trial | |
Japan | 2010280702 | STABILIZED FORMULATION OF ALPHA ADRENERGIC RECEPTOR ANTAGONISTS AND USE THEREOF | ⤷ Try a Trial |
South Africa | 200209811 | Local anesthetic methods and kits. | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |